The Silicon Review ^Asia

InnAccel aims to deliver respiratory support to newborns that would relieve them of their respiratory problems occurring at the time of shifting them to super-speciality hospitals from primary health care centres. In order to do that, the Bengaluru based startup has come up with its portable neo-natal CPAP (Continuous Positive Airwave Pressure) systemcalled as SAANS that is infrastructure independent as well.

SAANS has been developed by InnAccel’s own division, Coeo Labs, and is the only CPAP device that supports multiple power options as well as a patented manual mode. The device doesn’t require any high level of expertise to operate and can be highly effective to reduce one of the country’s major causes of infantmortality. The company has said that the product has been conceptualized in collaboration with Dr. Kristian Olson (USA) and Dr. Data Santorino (Uganda) of the Consortium of Affordable Medical Technologies (CAMTech).

SAANS is developed keeping the transport and secondary care settings in view so that the CPAP device can yield unblended air as output, i.e. an air-oxygen mixture or oxygen as needed. This enables physicians to regulate the flow and pressure of air according to the suggested ranges for neonatal CPAP. Currently, the product is going through clinical evaluation. It has been tested on a few neonates and the results have been promising with a survival rate of 100%.

With SAANS, InnAccel hopes to target rural areas where babies fail to receive CPAP treatment due to limited facilities. Moreover, the current CPAP devices are expensive and can only be used in the Neo-natal Intensive Care Unit (NICU). InnAccel wants to eliminate this gap in the market.